Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Richard A. Miller net worth and biography

Richard Miller Biography and Net Worth

CEO of Corvus Pharmaceuticals

Dr. Miller was co-founder and CEO of Pharmacyclics, where he led the initial discovery and development efforts for ibrutinib. Prior to that, he was a co-founder, Vice President and Director of IDEC (which merged to form Biogen IDEC, now Biogen), where he led research efforts on lymphoma culminating in the development of rituximab. He has also founded other private and public biotech companies. Dr. Miller received an M.D. from the State University of New York Medical School. He is a board-certified oncologist and is currently Adjunct Clinical Professor of Medicine (oncology) at Stanford University Medical Center.

What is Richard A. Miller 's net worth?: The estimated net worth of Richard A. Miller is at least $2.25 million as of May 6th, 2024. Dr. Miller owns 577,634 shares of Corvus Pharmaceuticals stock worth more than $2,252,773 as of December 18th. This net worth estimate does not reflect any other investments that Dr. Miller may own. Additionally, Dr. Miller receives an annual salary of $116,310.00 as CEO at Corvus Pharmaceuticals. Learn More about Richard A. Miller 's net worth.
How old is Richard A. Miller ?: Dr. Miller is currently 73 years old. There are 3 older executives and no younger executives at Corvus Pharmaceuticals. Learn More on Richard A. Miller 's age.
What is Richard A. Miller 's salary?: As the CEO of Corvus Pharmaceuticals, Inc., Dr. Miller earns $116,310.00 per year. There are 2 executives that earn more than Dr. Miller . The highest earning executive at Corvus Pharmaceuticals is Mr. Leiv Lea, Chief Financial Officer, who commands a salary of $400,210.00 per year. Learn More on Richard A. Miller 's salary.
How do I contact Richard A. Miller ?: The corporate mailing address for Dr. Miller and other Corvus Pharmaceuticals executives is 863 Mitten Road Suite102, BURLINGAME CA, 94010. Corvus Pharmaceuticals can also be reached via phone at (650) 900-4520 and via email at [email protected]. Learn More on Richard A. Miller 's contact information.
Has Richard A. Miller been buying or selling shares of Corvus Pharmaceuticals?: Richard A. Miller has not been actively trading shares of Corvus Pharmaceuticals during the last ninety days. Most recently, on Monday, May 6th, Richard A. Md Miller bought 577,634 shares of Corvus Pharmaceuticals stock. The stock was acquired at an average cost of $1.73 per share, with a total value of $999,306.82. Following the completion of the transaction, the chief executive officer now directly owns 577,634 shares of the company's stock, valued at $999,306.82. Learn More on Richard A. Miller 's trading history.
Are insiders buying or selling shares of Corvus Pharmaceuticals?: During the last year, Corvus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 597,634 shares worth more than $1,033,906.82. The most recent insider tranaction occured on May, 6th when insider William Benton Jones bought 20,000 shares worth more than $34,600.00. Insiders at Corvus Pharmaceuticals own 31.3% of the company. Learn More about insider trades at Corvus Pharmaceuticals.
Information on this page was last updated on 5/6/2024.

Richard A. Miller Insider Trading History at Corvus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/6/2024	Buy	577,634	$1.73	$999,306.82	577,634
12/13/2022	Buy	50,000	$0.74	$37,000.00	1,480,119
9/28/2022	Buy	25,000	$0.76	$19,000.00	1,394,405
9/20/2022	Buy	20,000	$0.81	$16,200.00	1,369,405
6/27/2022	Buy	5,000	$1.00	$5,000.00	1,349,405
6/24/2022	Buy	5,000	$1.03	$5,150.00	1,344,405
6/6/2022	Buy	890	$1.01	$898.90	1,339,405
6/2/2022	Buy	5,000	$0.98	$4,900.00	1,338,515
3/31/2022	Buy	15,000	$1.64	$24,600.00
3/17/2022	Buy	5,000	$1.59	$7,950.00
3/15/2022	Buy	25,000	$1.47	$36,750.00
8/20/2021	Buy	10,000	$1.93	$19,300.00	35,714
2/17/2021	Buy	100,000	$3.50	$350,000.00
11/12/2019	Buy	272	$2.90	$788.80
8/7/2019	Buy	7,500	$3.56	$26,700.00
6/13/2019	Buy	343	$3.52	$1,207.36
6/11/2019	Buy	15,212	$3.49	$53,089.88
6/7/2019	Buy	9,212	$3.37	$31,044.44
12/27/2018	Buy	20,000	$3.29	$65,800.00
12/27/2018	Buy	20,000	$3.29	$65,800.00
12/20/2018	Buy	10,000	$4.40	$44,000.00
12/6/2018	Buy	5,000	$5.99	$29,950.00
12/4/2018	Buy	1,502	$5.95	$8,936.90
3/12/2018	Buy	100,000	$8.50	$850,000.00
11/20/2017	Buy	10,000	$10.79	$107,900.00
6/13/2017	Buy	25,000	$9.88	$247,000.00
5/13/2016	Buy	30,300	$10.00	$303,000.00

Richard A. Miller Buying and Selling Activity at Corvus Pharmaceuticals

Corvus Pharmaceuticals Company Overview

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Today's Range

Now: $3.90

$3.77

$5.20

50 Day Range

MA: $8.18

$5.81

$9.56

2 Week Range

Now: $3.90

$1.30

$10.00

Volume

9,573,830 shs

Average Volume

443,147 shs

Market Capitalization

$250.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

First JFK… next Elon?

From Porter & Company | Ad